



MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021

The following management's discussion and analysis ("MD&A") of financial results is dated November 29, 2021 and reviews the business of BacTech Environmental Corporation (the "Company" or "BacTech"), for the three and nine months ended September 30, 2021, and should be read in conjunction with the accompanying condensed interim consolidated financial statements and related notes for the three and nine months ended September 30, 2021, as well as the audited annual financial statements for the year ended December 31, 2020 and related notes and MD&A. This MD&A and the accompanying condensed interim consolidated financial statements and related notes for the three and nine months ended September 30, 2021 have been reviewed by the Company's Audit Committee and approved by the Company's Board of Directors.

This MD&A contains certain forward-looking statements, such as statements regarding potential mineralization, resources and research results, and future plans and objectives of the Company, that are subject to various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements contained herein are made as of the date of this MD&A and the Company disclaims, other than as required by law, any obligation to update any forward-looking statements whether because of new information, results, future events, circumstances, or if management's estimates or opinions should change, or otherwise.

A. Core Business Strategy

BacTech Environmental Corporation was incorporated by REBgold Corporation ("REBgold" and formerly known as BacTech Mining Corporation) on October 5, 2010 under the *Canada Business Corporations Act*. Through the completion of the Plan of Arrangement, the Company was granted a perpetual, exclusive, royalty free license to use REBgold Corporation's proprietary bioleaching technology ("BACOX") in the remediation business for mining wastes and was listed on what is today the Canadian Stock Exchange under the symbol "BAC".

The BACOX technology utilizes bacteria to liberate precious and base metals and has been traditionally used to treat difficult-to-treat sulphide ores and concentrates. The business plan for the Company is to apply the bioleaching technology to the treatment of concentrates produced by gold mines and reclamation projects to remove harmful elements such as arsenic and sulphur from the environment, where this can be assisted by a positive cash flow from metal recovery. Examples of metals which can be extracted include gold, silver, cobalt, nickel, copper, uranium, and zinc.

Bioleaching is an environmentally friendly process technology for treating difficult-to-treat sulphide ores and concentrates. By replacing smelting and/or roasting with a bioleach process, the production of sulphur dioxide emissions, which is the primary source of acid rain, and arsenic trioxide are


eliminated. In addition, the removal of sulphide minerals from tailings compounds reduces the chance of acid rock drainage into the local environment. Furthermore, the capital and operating costs of a bioleach facility are significantly less when compared to other existing treatment methods.

B. Mineral Processing

Ecuador

BacTech has identified the Ponce Enriquez area of southern Ecuador as an area where the Company’s bioleaching technology can be successfully deployed for environmental processing of locally produced concentrates. Given the high levels of arsenic contained in the ore from the area, miners receive significantly reduced prices for their concentrates due to penalties applied by the buyers. The buyers tend to be from Asia where concentrates are shipped for conventional smelting and/or roasting. The concentrates are subject to a 3% export royalty on the gold value payable by the miner to the Government of Ecuador. BacTech believes that by implementing an in-country bioleach solution it can offer superior pricing for these concentrates to the local producers, better payment terms, provide domestic Ecuadorian employment opportunities. It should be noted that the final arsenical product resulting from bioleaching, ferric arsenate, is a US Environmental Protection Agency approved land-fillable form of arsenic.

Plans for Ecuador



The initial capacity for the proposed plant would be 50 tonnes per day (“tpd”) of arsenopyrite and refractory pyrite concentrates. At this stage the Company will be pursuing its goals with 100% ownership, but BacTech would consider a joint venture partner going forward. BacTech will act strictly as a purchaser and processor of third party concentrates and will not own any mineral properties in Ecuador. The current size of the market is 200-250 tpd of concentrate.

In the above chart we can see that the first step in the process involves ear-marking suitable concentrates for which a detailed bioleach test program will be undertaken. The Company collected samples from 6 different mines in the area from which 3 were selected as candidates for bioleaching. These samples were assayed for gold and arsenic content before being subjected to bioleach test work carried out at ALS Labs in Perth, Australia. A first step in the process is completion of a diagnostic leach study to get a better understanding of the leachability of the gold. On April 21, 2021, BacTech announced that it has achieved gold recoveries of over 99%. The estimated time to complete the test work is 16-20 weeks after which BacTech would establish the projected gold recovery and sulphide oxidation ratios as well as gaining a good understanding of the flow sheet for the plant.

Bio-Oxidation Kinetics

Bioleach test work on material collected from small mine producers in Ponce Enriquez, Ecuador, previously assayed to confirm positive magnitudes of gold, was completed on June 23rd, 2021. No unusual phenomenon was encountered during the testing compared to other feedstocks. The results are particularly encouraging, given the fact that some of the feedstocks were pretreated with cyanide by the miner to obtain any free gold present. Cyanide contaminated concentrates with high arsenic content are recognized as more difficult to treat due to toxicity phenomenon. A specialized pre-washing process was used to mitigate the toxicity effects of any residual cyanide species present in these feedstocks on the bio-oxidation process. A further positive attribute is that due to the low amount of inert siliceous gangue present in the feedstocks, a high weight loss was noted in the bio-oxidation testing. This has positive process implications in reducing the size of equipment required for downstream gold recovery and hence capital and operating costs.

Gold Recovery

Cyanidation work was conducted on the bio-oxidized residues at an independent lab to quantify the amount of gold that was liberated using bioleaching. Previous diagnostic test results received from ALS Laboratories on 20 April showed that if the feedstocks are oxidized to extinction, then 99% of the gold can be recovered. On July 19th the Company released the expected recovery rates for gold from bioleaching. In a program designed with added rigor to test the entire commercial process, final results showed a range of 95.5 to 96.5% gold recovery on the samples of arsenopyrite and pyrite.

Samples were either tested individually or as a blend, in order to confirm the process flexibility for managing various treatment scenarios in which a range of feedstocks with different compositions would be delivered to the plant. The table below shows the gold recoveries obtained from the tests conducted using a variety of feedstock combinations. The arsenic content of all the feedstock combinations tested was very high.

Feedstock Supplied to the Test	Feedstock Gold Head Grade (g/t)	Feedstock Arsenic Content (%)	Bio-oxidized Gold Grade for CIL processing (g/t)	Tail Gold Grade After CIL Gold Extraction (g/t)	Gold Recovery (%)
Conc.1+ Conc.3	54.6	16	55.0	2.15	96.1
Conc. 5	21.7	12.9	28.1	1.27	95.5
Conc.1+ Conc. 3 +Conc. 5	39.6	14.6	52.8	1.92	95.4

Bioleach Liquor Neutralization

This study will validate model predictions for reagent requirements of limestone (CaCO) and other reagents. Limestone (or lime) will be added to the post bioleach solution to raise the pH enabling precipitation of the iron and arsenic to form a stable ferric arsenate precipitate recognized by the USEPA and similar bodies as being environmentally benign and suitable for disposal. This test work will also produce a clean water for recycling to the process and the final solutions from neutralization will be assayed to ensure compliance for re-use.

Environmental Testing

TCLP testing focuses on the arsenic precipitate produced from the neutralization process to confirm resulting ferric arsenate is in compliance with the Toxicity Characteristic Leaching Procedure (“TCLP”) standards and the US EPA’s standards for deposition of waste materials. BacTech intends to transform harmful contaminants into benign EPA-approved products and the results from this test work will contribute to environmental approval for the project and process permitting. On August 30, 2021, BacTech announced the final bioleaching test results showing the successful neutralization of bio-oxidation liquors and TCLP stability testing of ferric arsenate precipitates. Four neutralization tests were performed on two final bio-oxidation liquors from the Ecuadorian commercial bioleach testing program, confirming that an environmentally stable ferric arsenate precipitate could be produced. The neutralization process, where limestone is added and calibrated to raise the pH of the bioleach liquor to facilitate the precipitation of the ferric arsenate, conclusively demonstrated that the precipitate passes the TCLP (Toxicity Characteristic Leaching Procedure) requirements for stability set out by the U.S. Environmental Protection Agency (“EPA”).

Feasibility Study for Ponce Enriquez

On July 28, 2021, BacTech announced it had engaged EPCM Consultores S.R.L. (“EPCMC”) to lead the feasibility study (“FS”) for the Company’s Ponce Enriquez, Ecuador bioleaching project. EPCMC is a South American engineering and development firm specializing in mining and metallurgical projects. EPCMC has considerable experience in a range of professional engineering services including feasibility studies, project design and construction within South America and Europe, having delivered close to 50 major projects and working with various international mining companies including Orvana, Silver Standard, Aquila Resources and Yamana Gold.

The FS will consider the proposed environmental setting and entire project infrastructure, along with sample collection and final bioleach test work results, to produce conceptual plans and estimates that encompass plant design, constructability, process economics expectations and scheduling. This study is expected to be simplified by the fact that there are no mining requirements to consider. Upon completion, the FS will provide the company with the information required to make a definitive decision on the bioleach plant location - culminating with the final representation of the plant build and operational planning requirements.

Using the flow sheet developed by the bioleach test work, the final piece of this phase of the project would be detailed engineering. It is our intent to rely heavily on the designs from previous plants that BacTech has built which addressed material with very similar mineralogical structure.

BacTech has now placed on option to purchase a parcel of land to be used for the operations in Ponce Enriquez. Applications will be made to the Ministries of Mining, Water and Environment, for approval of a water usage license, and tailings approval for the post bioleach residues.

We estimate that the cost to get the project to a “shovel ready” state will be approximately US\$800,000. The actual budget for construction, procurement and materiel is estimated to be \$US 15M with a 20% variance, based on costs from past projects. The detailed engineering will allow the company to reduce the variance in the budget. The estimated time to complete the pre-construction studies is approximately 12 months with the permitting being the longest part of the process. At the end of this process BacTech will actively pursue contractual concentrate feeds from local sources and quite possibly from neighboring countries such as Peru. Once the Company successfully completes the initial plant, it is conceivable we will attract enough feed to exceed the plant’s capacity. The current output from the Ponce

Enriquez area is estimated to be 200-250 tpd of gold/arsenic concentrates. This could lead to a straightforward expansion as BacTech's plants are modular in design.

Bolivia

On May 24, 2016, BacTech announced that its 98% owned Bolivian subsidiary, EMABSA, had signed an Association Contract with COMIBOL, the state mining company of Bolivia. On September 15, 2016, the Bolivian government by Law N degrees 831, approved and ratified the agreement.

On September 9, 2019, BacTech announced that it will not proceed with the reclamation of the Telamayu tailings project in Bolivia. After completing metallurgical test work on the project and evaluating the economics of the project it was decided that the project would be too difficult to finance. It was estimated that the project would cost approximately \$US 9M.

The inability to recover tin into a suitable concentrate severely hampered the economics of the project. Given the fact that the value of the tin made up roughly 50% of the value of the contained metal in the tailings, financing the project was deemed to be too difficult.

Other Projects

The Company continues to evaluate other projects in South America and Central America.

On May 15, 2019, BacTech announced that it had signed a letter of intent with GMR Inc. ("GMR") to license BacTech's proprietary bioleach technology. BacTech joins Dundee Sustainable Technologies (CSE: DST) as a technology partner with GMR to develop a potential solution for the remediation of the Gold Residual Stockpile in Snow Lake, Manitoba. Through this agreement, BacTech received a \$20,000 cash payment as an advance for the right to utilize the BacTech proprietary bioleach technology on the Gold Residual Stockpile in Snow Lake, Manitoba. In addition, BacTech will earn 3% undivided equity interest in the net income of the project. GMR is relying on BacTech's historical research conducted in 2011 and 2012 that showed oxidation rates of 95% and gold recovery of 88.6% on material obtained from the arsenic stockpile.

Colombia

On August 10, 2020, the Company announced that it has agreed to participate in an evaluation of mine tailings near Medellin, Colombia. The grades of gold and platinum were very high compared to normal tailings grades. Even though MetalTec LLC, the prospective partner company, provided assay results from ALS Laboratories, it was decided that an independent contractor should be engaged to conduct an arm's length study of the tonnage and grade of contained metal. The tailings also contain 1% arsenic. There has been little development of this project due to Covid-19 and unstable political conditions in Colombia.

East Africa

On April 26, 2021, the Company announced that it has executed a strategic Memorandum of Understanding ("MOU") with Curatio Gold Limited ("Curatio") to source refractory ores for processing from Eastern Africa. Curatio was recently established to provide funding to support improved metallurgical processing, with the goal of eliminating the dangerous and environmentally unfriendly use of mercury for gold liberation. The group will initially focus its efforts in East Africa on an active Artisanal and Small-scale mining ("ASM") industry. The principal founders of Curatio have many years of technical mining

expertise and are well versed in supporting small and medium-sized businesses in Africa. Curatio CEO Doug Ramsey, R.P.Bio., is a biologist with expertise in environmental mercury concerns and four decades of experience in solving mining related environmental issues. Prior to founding Curatio with Mark Francis, Doug was CEO and VP Sustainability with a junior miner and a consultant to industry and government

C. Results of Operations

This analysis of the results of the Company's operations should be read in conjunction with the Company's condensed interim consolidated financial statements for the nine months ended September 30, 2021.

Revenues

The Company has no revenue or sources of recurring revenues.

Operating and Administrative Costs

Operating and administrative expenses increased to \$792,788 for the nine months ended September 30, 2021 from \$229,231 in the same period last year. Significant components of this expense include:

1. Salaries and management fees increased to \$125,972 for the nine months ended September 30, 2021 from \$41,631 in the same period last year. These costs are for the salaries and management fees incurred directly in managing and operating the business of the Company.

The officers and a consultant of the Company forgave the debt owing to them from accrued salaries and management fees effective June 30, 2020. As a result, no salaries or fees were earned in the six months ended June 30, 2020 and all related debt owing to them from accrued salaries from previous years were written down to \$Nil. Common share stock options were issued as compensation for the cancellation of the accrued salaries;

2. Share-based payments, as explained in note 12 to the condensed interim consolidated financial statements, were \$398,300 for the nine months ended September 30, 2021 and \$74,900 for year ended December 31, 2020. Yearly fluctuations in stock option expense are dependent on several factors including, but not limited to, number of options issued, valuation of options, vesting period and timing. For the year ended December 31, 2020, the Company granted 2,500,000 options (primarily in consideration of the forgiveness of the debt as explained above). For the nine months ended September 30, 2021, the Company granted 4,100,000 options .
3. Professional fees increased to \$151,205 for the nine months ended September 30, 2021 from \$50,882 in the same period last year. The increase in professional fees is due to an increase in activity pursuing the development of the Ecuador project. These expenses are indirect expenses (legal, strategic advisory and consulting) and not included in project costs.
4. Travel costs increased to \$15,924 for the nine months ended September 30, 2021, from \$360 in the same period last year. Travel expenditures were reduced and kept to a minimum because of the current pandemic. Travel has been limited to Ecuador in the current period; and
5. Shareholder information and filing fees expenses increased to \$66,093 for the nine months ended September 30, 2021, from \$46,417 in the same period last year. This type of expense was reduced, starting in fiscal 2019, and the trend has continued until this quarter. Additional expenditures have been incurred to update the company video in multiple languages, improve website and improve distribution of news flow to European investors.

Project Expenditures

The project expenditures were for the diagnostic and bioleaching test work for the Ecuador project, as well the start of the feasibility work that was initiated in the current period.

Finance Charges and Debentures

Finance charges are made up of interest charged by suppliers and vendors, loans payable and the debentures payable.

For the loan payable of \$150,000, interest expenses for the nine months ended September 30, 2021 was \$41,625 (2020 -\$41,625). This loan continues to accrue interest at a rate of 1.5% per month compounded monthly.

Between April 19, 2017, and September 26, 2017, BacTech completed three tranches of a debenture financing for gross proceeds of \$445,000. This debenture included bonus interest in the form of common shares. This debenture has generated interest expense of \$34,050 and accretion expense of \$2,865 for the nine months ended September 30, 2021. For the debenture holders that have reached their maturity date in fiscal 2019, the Company requested that the debenture holders extend the term of the debentures. In consideration of the extension of the maturity date, the Company has offered to issue a common share purchase warrant allowing the debenture holders to purchase a common share of the Company at five cents for a period of three years for each \$0.05 of debenture held. In fiscal 2020, \$20,000 of the debenture holders formally accepted the terms to extend the maturity date. A total of 496,000 warrants were issued at a value of \$6,072. Redemptions of the debentures for the nine months ended September 30, 2021 increased by \$25,000 to total of \$112,500 redemptions to date.

On November 29, 2017, BacTech completed a debenture financing for gross proceeds of \$100,000 and accompanied it by the issuance of 400,000 common shares, which are included as a bonus equity interest and NSR of 0.50% in relation to the project in Bolivia. The debenture has a 2-year term and pays 12% interest. This debenture has generated interest expense of \$9,000 and accretion expense of \$9,000 for the nine months ended September 30, 2021. The debenture holder reached their maturity date in fiscal 2019. The Company requested that the debenture holder extend the term of the debentures. In consideration of the extension of the maturity date, the Company has offered to issue a common share purchase warrant allowing the investor to purchase a common share of the Company at five cents for a period of three years for each \$0.05 of debenture held. In fiscal 2020, the debenture holder formally accepted the terms to extend the maturity date. A total of 2,480,000 warrants were issued at a value of \$21,300.

On May 14, 2018, BacTech completed a debenture financing for gross proceeds of \$85,000. The debentures were accompanied by the issuance of 340,000 common shares which are included as a bonus equity interest and NSR of 2.50% in relation to the project in Bolivia. The debenture has a 2-year term and pays 12% interest. This debenture has generated interest expense of \$7,650 and accretion expense of \$10,800 for the and nine months ended September 30, 2021. The debenture holders reached their maturity date in fiscal 2020. The Company requested that the debenture holders extend the term of the debentures. In consideration of the extension of the maturity date, the Company has offered to issue a common share purchase warrant allowing the investor to purchase a common share of the Company at \$0.05 for a period of two years for each \$0.05 of debenture held. In fiscal 2020, the debenture holders formally accepted the terms to extend the maturity date. A total of 2,108,000 warrants were issued at a value of \$28,400.

On May 1, 2019, the Company closed a \$150,000 Senior Bridge Debenture. The Senior Bridge Debenture is for one year and will pay 12% interest on redemption. This debenture included warrants. This debenture has generated interest expense of \$10,440 and accretion expense of \$40,710 for the nine months ended September 30, 2021. The Senior Bridge Debentures holders reached their maturity date in fiscal 2020. The Company requested that the debenture holders extend the term of the debentures. In consideration of the extension of the maturity date, the Company has offered to issue a common share purchase warrant allowing the investor to purchase a common share of the Company at \$0.05 for a period of two years for each \$0.05 of debenture held. In fiscal 2020, the debenture holders formally accepted the

terms to extend the maturity date. A total of 3,360,000 warrants were issued at a value of \$61,070. During the nine months ended September 30, 2021, BacTech repaid the principal balance of \$75,000 plus interest to one of the convertible debentures holders that was completed on May 1, 2019. The remaining principal amount of the Senior Bridge Debentures owing by the Company is now \$75,000.

Cash Flow Comparison

Cash flow from financing activities: For the nine months ended September 30, 2021, the Company completed two equity private placements for gross proceeds of \$275,057, from the exercise of options and warrant received proceeds of \$638,559, as well as repaid a debenture principal amount of \$75,000.

Cash flow from operating activities: This represents the cash paid for overhead expenditures and project expenditures. These payments were financed from the sources of cash in financing activities.

D. Liquidity and Capital Resources

At September 30, 2021, the Company had cash of \$195,607 and a working capital deficit of \$2,354,606.

On November 1, 2021, BacTech announced that it had reached agreements with 83.1% of its current debenture and loan payable holders to convert \$642,500 of the Company's outstanding debt and \$557,585 accrued interest into 12,000,854 Units. Each Unit, priced at \$0.10 per Unit, is comprised of one common share and one common share purchase warrant, exercisable at \$0.20 for 2 years, in the capital of the Company.

On October 15, 2021, BacTech announced it had closed its previously announced private placement for gross proceeds of \$331,250 through the issue of 3,312,500 Units. Each Unit, priced at \$0.10 per Unit, is comprised of one common share and one common share purchase warrant in the capital of the Company.

During the nine months ended September 30, 2021, a total of 1,100,000 common share stock options were exercised at a price of \$0.07 providing gross proceeds of \$77,000 to the Company. Furthermore, a total of 11,231,157 common share purchase warrants were exercised providing gross proceeds of \$561,559 to the Company.

On February 2, 2021, BacTech announced the closing of the second round of financing using the Regulation "A" exemption. In this round the Company raised US\$94,500 at US\$0.015 per share through the issuance of 6,300,000 common shares.

On February 5, 2021, BacTech announced that it closed the previously announced, non-brokered private placement. A total of \$153,500 was raised through the issuance of 5,116,666 common shares priced at \$0.03 per share. Four insiders of BacTech participated in this financing for a total of \$39,000 resulting in the issuance of 1,300,000 common shares.

On July 15, 2020, the Company's Tier 2 Regulation A offering memorandum originally filed on April 2, 2020, with the United States Securities and Exchange Commission (SEC) was qualified. The share price for the first tranche is US\$0.0150. On September 15, 2020, the Company closed its first tranche for gross proceeds US\$50,000 through the issuance of 3,333,333 common shares.

On February 13, 2020 and March 20, 2020, the Company completed a private placement for total gross proceeds of \$64,000 through the issue of 4,266,667 units at a price of \$0.015 per unit. Each unit consisted of one common share of the Company and one full common share purchase warrant exercisable at \$0.05 for 2 years.

Share Capital				
	September 30, 2021		December 31, 2020	
	Number of shares	\$ Amount	Number of shares	\$ Amount
Balance, beginning of period	116,914,381	5,787,147	101,153,756	5,470,659
Shares issued from private placements	5,116,666	153,500	4,266,667	64,000
Shares issued from Reg A financing	6,300,000	121,557	3,333,333	65,880
Shares issued from debenture conversion	680,000	34,000	-	-
Shares pursuant to exercise of warrants and options	12,331,157	638,559	8,160,625	244,819
Shares issued for debt	-	-	-	-
Fair value of warrants and options	-	151,702	-	-
Less share issue costs				
Fair value of warrants	-	-	-	(29,850)
Share issue costs	-	(3,111)	-	(28,361)
Balance, end of period	141,342,204	6,883,354	116,914,381	5,787,147

For a description of the outstanding warrants and stock options that are outstanding to purchase common shares of the Company, please refer to Note 11 - Share Capital, Note 12 – Warrant, and Note 13 – Stock Options of the condensed interim consolidated financial statements.

E. Quarterly Information

Selected quarterly information for the most recently completed quarter is presented below in Canadian currency (\$), and in accordance with International Financial Reporting Standards.

	2021			2020				2019
	Q3 \$000's	Q2 \$000's	Q1 \$000's	Q4 \$000's	Q3 \$000's	Q2 \$000's	Q1 \$000's	Q4 \$000's
License fees	-	-	-	-	-	-	-	-
Other items	-	-	-	-	163	1,220	-	-
Net Loss for the period	(427)	(252)	(398)	(159)	1	1,191	(172)	(193)
Loss per share (0.00)	(0.005)	0.00	(0.005)	0.00	0.00	0.01	0.00	0.00

F. Off-Balance Sheet Arrangements

The Company had no off-balance sheet arrangements as of September 30, 2021.

G. Financial Instruments

The Company has not entered into any specialized financial arrangements to minimize its investment risk, currency risk or commodity risk.

H. Outlook

While the volatility in the capital markets and markets for metals has subsided, the resource sector has relatively fallen from favour with investors making capital raising in the sector more difficult than it has traditionally been for junior companies in the resource sector and in the remediation and reclamation of mine waste and tailings. There can be no assurance that the Company will be successful in attracting either new financing or new opportunities to apply its technology.

I. Risks

The Company's strategy emphasizes developing projects to leverage its intellectual property to create shareholder value. This strategy has required, and continues to require, significant financings, and is subject to risks associated with mineral prices, mineral resources and operations. Due to the nature of the Company's business, the present stage of development of its projects, and the constraints placed upon the Company's ability to move forward by its current liquidity situation, readers should carefully review and consider the financial, environmental and operational risk factors affecting the Company.

COVID-19 Pandemic

The Company is subject to various market, political and regulatory constraints as a result of the COVID-19 situation and additional business and financial risks that may result therefrom. The duration of the COVID-19 outbreaks and the resultant travel restrictions, social distancing, Government response actions, business closures and disruptions, can all have an impact on the Issuer's operations and access to capital. There can be no assurance that the Issuer will not be impacted by adverse consequences that may be brought about by the COVID-19 pandemic on global financial markets, share prices and financial liquidity and that may severely limit the financing capital available to the Company. While it appears that the pandemic is continuing longer than might originally have been expected, adaptation to the new requirements of a pandemic affected world seems generally to be taking place. The suggestion of general availability of vaccines in Canada with a good vaccination rate, but very different around the world and, therefore, continued uncertainties, but with some surprisingly good economic recoveries.

Need for Additional Financing

The Company currently has no source of operating cash flow, and there is no assurance that additional funding will be available to the Company as and when needed for further assessment and evaluation, as well as development of its projects, or to fulfill its obligations to its existing creditors. Volatile markets may make it difficult or impossible for the Company to obtain adequate debt or equity financing in the future, or on terms acceptable to the Company. The failure to obtain additional financing could force the Company to liquidate its assets to satisfy creditor claims.

Dependence on Management

The Company's business and operations are dependent on recruiting and retaining the services of a small number of key members of management and qualified personnel. The success of the operations and activities of the Company are dependent, to a significant extent, on the efforts and abilities of the management of the Company. Investors must be willing to rely, to a significant extent, on the discretion and judgment of the management of the Company. Furthermore, while the Company believes that it will be successful in attracting qualified personnel and retaining its current management team, there can be no assurance of such success. The Company does not maintain key employee insurance on any of its employees.

Competition

The Company competes with other engineering companies for the acquisition of mineral rich mine tailings and mine waste that can be developed economically. The Company competes with other engineering companies that have greater financial and technical resources and experience. Such competition may result in the Company being unable to acquire desired properties, to recruit or retain qualified employees, or to acquire the capital necessary to fund its operations and develop its properties. The inability of the Company to compete with other engineering companies for these resources would have a material adverse effect on the Company's results of operations and business.

Currently, the Company's bioleaching technology does not operate in an overly competitive marketplace; however, the Company anticipates that it may face increased competition in the future, as advanced technologies become available. While management believes that the Company's technology is more advanced, commercially proven and better situated than its competitors, there can be no assurance that the Company will be able to effectively compete with companies who have or may develop similar technologies and may possess greater financial resources and technical facilities. Competitive pressures, or the inability of the Company to successfully license its technology on terms that are acceptable, may have a material adverse effect on the Company's business, operating results and financial condition.

Protection of Intellectual Property Rights

The Company is dependent not only on its ability to protect its intellectual property rights, but also upon the protection of rights of third parties from which it may license intellectual property rights. The Company currently holds patent rights and has pending patent applications. In addition, the Company relies upon certain other technologies, ideas; know how, secrets or other information, which it may not be able to protect. Notwithstanding precautions the Company may take to protect its rights, third parties may copy or obtain and use the Company's proprietary and licensed or optioned technologies, ideas, know how, secrets and other proprietary information without authorization or independently develop technologies similar or superior to the Company's proprietary and licensed or optioned technologies. The Company enters confidentiality and restriction on use agreements with its employees, strategic partners, and others; however, these agreements may not provide meaningful protection of the Company's proprietary and licensed or optioned technologies or other intellectual property in the event of unauthorized use or disclosure. Policing unauthorized use of such technologies and intellectual property is extremely difficult, and the cost of enforcing the Company's rights through litigation may be prohibitive. Further, the laws of jurisdictions other than Canada and the United States may not provide meaningful protection of the intellectual property rights of the Company and such third parties.

Obtaining and Enforcing Patents

The patent positions of technology firms, including the Company, are generally uncertain and involve complex legal and factual questions. The Company's success in utilizing and licensing its bioleaching technology will depend, in part, on its ability to obtain, enforce and maintain patent protection for its technology worldwide. The Company cannot be assured that patents will issue from any pending applications or that claims now or in the future allowed under issued patents will be sufficiently broad to protect its technology. In addition, no assurance can be given that any patents issued to or licensed by the Company will not be challenged, invalidated, infringed, or circumvented, or that the rights granted thereunder will provide continuing competitive advantages to the Company. Furthermore, there is no assurance that the patents of others will not impede the ability of the Company to do business or that others will not independently develop similar products or technologies, duplicate any of the Company's products or technologies or, if patents are issued and licensed to the Company, design around the Company's patented product or technology.

Accordingly, the Company may not be able to obtain and enforce effective patents to protect its proprietary rights from use by competitors, and the patents of other parties could require the Company to stop using or pay to use certain intellectual property, and as such, the Company's competitive position and profitability could suffer as a result.

Claims of Infringement of Proprietary Rights of Others

The Company is not currently aware of any claims asserted by third parties that the Company's intellectual property infringes on their intellectual property. However, in the future, third parties may assert a claim that the Company infringes on their intellectual property. As a result, there is a risk that the Company, or one or more of its licensors, may become subject to litigation alleging that the products or technologies of the Company or its licensors infringe on the proprietary rights of third parties. Whether or not the products or technologies infringe on the proprietary rights of third parties, the Company or such licensors could incur significant expenses in defending allegations of infringement of proprietary rights. Further, the Company or such licensors may be required to modify their products or obtain licenses for intellectual property rights because of any alleged proprietary infringement which may not be achievable on commercially reasonable terms, in a timely manner, or at all, any of which could adversely affect the Company's business revenue, results from operations and financial condition.

Conflicts of Interest

Certain of the Company's directors and officers may serve as directors or officers of other reporting companies, companies providing services to the Company, or companies in which they may have significant shareholdings. To the extent that such other companies may participate in ventures in which the Company may participate, the directors of the Company may have a conflict of interest in negotiating and concluding terms respecting the extent of such participation. If such a conflict of interest arises at a meeting of the Company's directors, a director who has such a conflict will abstain from voting for or against the approval of such participation or such terms.

From time to time, several companies may participate in the acquisition, assessment and evaluation, and development of mineral reclamation properties, thereby allowing for the participation in larger programs, permitting involvement in a greater number of programs and reducing financial exposure in respect of any one program. It may also occur that a particular company will assign all or a portion of its interest in a particular program to another of these companies due to the financial position of the company making the assignment. In accordance with the laws of Canada, the directors of the Company are required to act honestly, in good faith and in the best interests of the Company. In determining whether the Company will participate in a program and the interest therein to be acquired by it, the directors will primarily consider the degree of risk to which the Company may be exposed and its financial position at the time.

J. Related Party Transactions

Please refer to Note 7 of the condensed interim consolidated financial statements for the three and nine months ended September 30, 2021.

K. Other MD&A Requirements

Additional information related to the Company is filed electronically on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.